CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases.
In 81 healthy women, 26 pregnant women, 25 patients with fibrocystic disease and 144 breast cancer patients, the overall diagnostic sensitivity and specificity of the CA 15.3 test was 27 and 97%, respectively. The positive and negative predictive values were 93 and 43%. In 150 node-negative patients taking part in a chemoprevention trial CA 15.3 was assayed at baseline and every 4 months for a median follow-up of 24 months (range 4-48). In these patients, 5 had local recurrences, 1 had a regional recurrence, 9 had distant metastases and 3 developed cancer in the contralateral breast. Among the patients with recurrences, those with distant metastases showed the highest ratio of CA 15.3 increase (8/9); in local and regional recurrences, this ratio was lower (2/6). The patients with contralateral breast cancer had no significant increase in CA 15.3. Patients in whom metastases were detected showed an increase in CA 15.3 4-48 months before clinical or instrumental detection of the metastases.
Bombardieri
E
E
Nuclear Medicine Department, National Cancer Institute, Milano, Italy.
Pizzichetta
M
M
Veronesi
P
P
Seregni
E
E
Bogni
A
A
Maffioli
L
L
Jotti
G S
GS
Bassetto
M A
MA
Zurrida
S
S
Costa
A
A
D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000276:immunology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D011237:Predictive Value of Tests; D011247:Pregnancy; D011446:Prospective Studies; D013997:Time Factors
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor